Fig. 8
RPL39 cooperates with AGK in function. A The silencing of RPL39 in OVCAR3-AGK cells was determined through Western blotting and real-time PCR. The overexpression of RPL39 in OVCAR3-AGK-RNAi cells was confirmed through Western blotting. Cell growth curve (B) and colony formation assay (C) indicated that the growth rate decreased in OVCAR3-AGK-siRPL39 cells and increased in OVCAR3-shAGK-siRPL39 cells. The number of cells on Day 2–6 was normalized to those on Day 1 as a control. The number of colonies was quantified through the colony formation assay. D Transmission electron microscopic analysis of OVCAR3-AGK-siNC and OVCAR3-AGK-siRPL39 cells. Scale bar was 1 μm. G Stably overexpressed and knocked-down RPL39 EOC cell lines (OVCAR3) were detected by WB. H Flow cytometry analysis of annexin V+/PI ̄ cells after the indicated cells were treated with cisplatin (80 μm/ml) for 24 h. Results were expressed as a percentage of total cells. I The dose-dependent curve of cisplatin treatment for OVCAR3-AGK-siNC and OVCAR3-AGK-siRPL39 cells. Error bars represent the means ± SD of 3 independent experiments. *P < 0.05. **P < 0.001. N = 3 independent experiments